Evidence map›Paper›PMID 35688404›Full record

ArticleThe international journal of biochemistry & cell biology2022

Dopamine D

Yang Yang, Mechelle M Lewis, Xuemei Huang, Nikolay V Dokholyan, Richard B Mailman

Abstract read
In one paragraph

Article in The international journal of biochemistry & cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Dopamine DNeuroscience · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang YangDepartment of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA. Electronic address: yangyang@psu.edu.
Mechelle M LewisDepartment of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.
Xuemei HuangDepartment of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Humanities, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Radiology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurosurgery, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Kinesiology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.
Nikolay V DokholyanDepartment of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.
Richard B MailmanDepartment of Pharmacology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Department of Neurology, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA; Translational Brain Research Center, Penn State Milton S. Hershey Medical Center and Penn State College of Medicine, Hershey, PA 17033, USA.

Funding

Discovery of functionally selective dopamine ligands for age-related cognitive declineRF1AG071675 · NIA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DOKHOLYAN, NIKOLAY, MAILMAN, RICHARD B · 2021 to 2021
$1.5M
In vivo agonist molecular probes for the dopamine D1 receptorR01NS105471 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAILMAN, RICHARD B, SHARMA, ARUN K · 2018 to 2020
$1.0M
Discovery of functionally selective dopamine ligands for age-related cognitive declineR01AG071675 · NIA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DOKHOLYAN, NIKOLAY, MAILMAN, RICHARD B · 2024 to 2025
$968k
NIA NIH HHS R01 AG071675NIA NIH HHS RF1 AG071675NINDS NIH HHS R01 NS105471
6 · The paper itself

Abstract

The awareness of the potential importance of functional selectivity/biased signaling has led to the discovery of biased compounds as both research tools and novel drugs. A major pan-receptor focus has been to identify GPCR-selective ligands that have bias in G protein-dependent vs. β-arrestin related signaling. Although this field has exploded during the past two decades, it is only recently that highly β-arrestin biased ligands for the dopamine D

Indexed as

ArrestinsDopamineAnimalsbeta-Arrestin 1beta-ArrestinsBiologyLigandsNeurophysiologySignal TransductionArrestinsbeta-Arrestin 1beta-ArrestinsDopamineLigandsDopamine D(1) receptorFunctional selectivityNeurophysiologyβ-arrestin

Identifiers

PMID35688404
PMCPMC10266066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.